Overcoming challenges to enable targeting of metastatic breast cancer tumour microenvironment with nano-therapeutics: Current status and future perspectives

Niveria, Karishma; Yadav, Monika; Dangi, Kapil; Verma, Anita

doi:10.1016/j.onano.2022.100083

Cited by 6 publications

(2 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EMT is portrayed by the combined loss of epithelial cell junction proteins, consisting of E-cadherin, α-catenin, claudins, occluding, and ZO-1. During EMT, there is an amplified expression of mesenchymal markers, including as N-cadherin, vimentin, and fibronectin, along with reorganization of the cytoskeleton, which collectively results in the loss of apical-basal cell polarity and the attainment of a spindle-shaped morphology [15][16][17][18].…”

Section: Nature and Pathophysiologymentioning

confidence: 99%

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics

Dissanayake

Towner

Ahmed

2023

Cancers

View full text Add to dashboard Cite

Metastases of breast cancer (BC) are often referred to as stage IV breast cancer due to their severity and high rate of mortality. The median survival time of patients with metastatic BC is reduced to 3 years. Currently, the treatment regimens for metastatic BC are similar to the primary cancer therapeutics and are limited to conventional chemotherapy, immunotherapy, radiotherapy, and surgery. However, metastatic BC shows organ-specific complex tumor cell heterogeneity, plasticity, and a distinct tumor microenvironment, leading to therapeutic failure. This issue can be successfully addressed by combining current cancer therapies with nanotechnology. The applications of nanotherapeutics for both primary and metastatic BC treatments are developing rapidly, and new ideas and technologies are being discovered. Several recent reviews covered the advancement of nanotherapeutics for primary BC, while also discussing certain aspects of treatments for metastatic BC. This review provides comprehensive details on the recent advancement and future prospects of nanotherapeutics designed for metastatic BC treatment, in the context of the pathological state of the disease. Furthermore, possible combinations of current treatment with nanotechnology are discussed, and their potential for future transitions in clinical settings is explored.

show abstract

Section: Nature and Pathophysiologymentioning

confidence: 99%

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics

Dissanayake

Towner

Ahmed

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In the metastatic process, cancer cells from the lungs can spread to distant sites including breasts, colon, or prostate. 11 Addressing metastasis proves challenging owing to the complex nature, characterized by factors like tumor heterogeneity and the unique tumor microenvironment (TME). The challenges posed by metastasis and tumor heterogeneity are further compounded by the distinctive characteristics of the tumor microenvironment in comparison to healthy tissues.…”

Section: Introductionmentioning

confidence: 99%

Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches

Aryal,

Park,

Park

et al. 2023

IJN

View full text Add to dashboard Cite

Lung cancer is one of the most common malignant tumors worldwide and is characterized by high morbidity and mortality rates and a poor prognosis. It is the leading cause of cancer-related death in the United States and worldwide. Most patients with lung cancer are treated with chemotherapy, radiotherapy, or surgery; however, effective treatment options remain limited. In this review, we aim to provide an overview of clinical trials, ranging from Phase I to III, conducted on drug delivery systems for lung cancer treatment. The trials included oral, inhaled, and intravenous administration of therapeutics. Furthermore, the study also talks about the evolving paradigm of targeted therapy and immunotherapy providing promising directions for personalized treatment. In addition, we summarize the best results and limitations of these drug delivery systems and discuss the potential capacity of nanomedicine.

show abstract